3 results
To demontrate improvement of progression-free survival (PFS) and/or overall survival (OS) with M7824 compared with pembrolizumab in first-line participants with advanced NSCLC with high PD-L1 tumor expression.
The aim of this study is to evaluate and describe the PK of fosfomycin in individuals receiving oral treatment with multiple dosages of fosfomycin for recurrent and/or complicatedurinary tract infection. The results of this study will be used to…
Main objective:- Evaluate the anti-tumor activity per RECIST 1.1 in participants with metastatic or locally advanced/unresectable urothelial cancer treated with bintrafusp alfa. Secondary objectives: - Evaluate other measures of antitumor activity…